(Q44453492)

English

Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome

scientific article published on 28 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

author name string

Lotta Ohm

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Ingrid Arvidsson

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gisela Barbany

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Robert Hast

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Leif Stenke

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

28 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

87

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

760-765

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

describes a project that uses

fluorescence in situ hybridization

1 reference

based on heuristic

inferred from title

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23238

21 January 2018

Identifiers

10.1002/AJH.23238

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44453492&oldid=2097430772"